• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Intra-Cellular Ther (NQ: ITCI )

    74.41 +0.87 (+1.18%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 582,666
    Open 73.86
    Bid (Size) 74.41 (18)
    Ask (Size) 74.48 (2)
    Prev. Close 73.54
    Today's Range 73.71 - 76.34
    52wk Range 45.50 - 84.89
    Shares Outstanding 94,324,313
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Expert Ratings For Intra-Cellular Therapies
    Via Benzinga
    This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
    Via Benzinga

    Performance

    YTD
    +5.56%
    +5.56%
    1 Month
    +1.09%
    +1.09%
    3 Month
    +7.73%
    +7.73%
    6 Month
    +13.72%
    +13.72%
    1 Year
    +26.81%
    +26.81%

    More News

    Read More
    Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
    Via Investor's Business Daily
    Topics Earnings
    Exposures Financial
    Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (9 Ratings)
    Via Benzinga
    Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
    Via PressReach
    Exposures Product Safety
    A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies
    Via Benzinga
    Where Intra-Cellular Therapies Stands With Analysts
    Via Benzinga
    NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
    Via Benzinga
    China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio?
    Via Benzinga
    Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
    Via Investor's Business Daily
    Patterson Companies, Silk Road Medical, Micron, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Analyst Ratings For Intra-Cellular Therapies
    Via Benzinga
    The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts
    Via Benzinga
    Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
    Via Benzinga
    Exposures Product Safety
    Intra-Cellular Therapies Eyes $1.7 Billion Opportunity After Phase 3 Win
    Via Investor's Business Daily
    The Secret Stock Stash: 3 Overlooked Picks That Belong in Every Portfolio
    Via InvestorPlace
    ITCI Stock Earnings: Intra-Cellular Therapies Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    3 Biotech Stocks With Skyrocketing Potential: April 2024
    Via InvestorPlace
    Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    How Is The Market Feeling About Intra-Cellular Therapies?
    Via Benzinga
    Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday
    Via Benzinga
    Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study
    Via Benzinga
    UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.